BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21370233)

  • 1. An evidence based strategy for follow up after breast conserving treatment for breast cancer.
    Kontos M; Roy P; Rizos D; Hamed H
    J Surg Oncol; 2011 Sep; 104(3):223-7. PubMed ID: 21370233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast-conserving therapy after neoadjuvant chemotherapy: long-term results.
    Beriwal S; Schwartz GF; Komarnicky L; Garcia-Young JA
    Breast J; 2006; 12(2):159-64. PubMed ID: 16509842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy.
    Truong PT; Jones SO; Kader HA; Wai ES; Speers CH; Alexander AS; Olivotto IA
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):357-64. PubMed ID: 18676091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy?
    Cebrecos I; Córdoba O; Deu J; Xercavins J; Rubio IT
    Eur J Surg Oncol; 2010 Jun; 36(6):528-34. PubMed ID: 20444571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation the significance of tumor size.
    Fodor J; Polgár C; Major T; Németh G
    Strahlenther Onkol; 2003 Mar; 179(3):197-202. PubMed ID: 12627264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (<40 years) women treated with breast conserving surgery first.
    Bollet MA; Sigal-Zafrani B; Mazeau V; Savignoni A; de la Rochefordière A; Vincent-Salomon A; Salmon R; Campana F; Kirova YM; Dendale R; Fourquet A
    Radiother Oncol; 2007 Mar; 82(3):272-80. PubMed ID: 17287037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy.
    Peintinger F; Symmans WF; Gonzalez-Angulo AM; Boughey JC; Buzdar AU; Yu TK; Hunt KK; Singletary SE; Babiera GV; Lucci A; Meric-Bernstam F; Kuerer HM
    Cancer; 2006 Sep; 107(6):1248-54. PubMed ID: 16862596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer.
    Tanis E; van de Velde CJ; Bartelink H; van de Vijver MJ; Putter H; van der Hage JA
    Eur J Cancer; 2012 Aug; 48(12):1751-6. PubMed ID: 22446021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The importance of the follow-up in patients operated on for breast cancer. A retrospective analysis of 2482 cases].
    Krengli M; Pastore G; Maffei S
    Minerva Med; 1993; 84(7-8):409-15. PubMed ID: 8414134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loco-regional recurrence after mastectomy in high-risk breast cancer--risk and prognosis. An analysis of patients from the DBCG 82 b&c randomization trials.
    Nielsen HM; Overgaard M; Grau C; Jensen AR; Overgaard J
    Radiother Oncol; 2006 May; 79(2):147-55. PubMed ID: 16647152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety of breast-conserving therapy in patients with breast cancer aged < or = 40 years.
    van der Leest M; Evers L; van der Sangen MJ; Poortmans PM; van de Poll-Franse LV; Vulto AJ; Nieuwenhuijzen GA; Brenninkmeijer SJ; Creemers GJ; Voogd AC
    Cancer; 2007 May; 109(10):1957-64. PubMed ID: 17394192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tailored follow-up for early breast cancer patients: a prognostic index that predicts locoregional recurrence.
    van Nes JG; Putter H; van Hezewijk M; Hille ET; Bartelink H; Collette L; van de Velde CJ;
    Eur J Surg Oncol; 2010 Jul; 36(7):617-24. PubMed ID: 20558026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term results with breast-conserving therapy for patients with early stage breast carcinoma in a community hospital setting.
    Kini VR; White JR; Horwitz EM; Dmuchowski CF; Martinez AA; Vicini FA
    Cancer; 1998 Jan; 82(1):127-33. PubMed ID: 9428488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.
    Poggi MM; Danforth DN; Sciuto LC; Smith SL; Steinberg SM; Liewehr DJ; Menard C; Lippman ME; Lichter AS; Altemus RM
    Cancer; 2003 Aug; 98(4):697-702. PubMed ID: 12910512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation.
    Solin LJ; McCormick B; Recht A; Haffty BG; Taylor ME; Kuske RR; Bornstein BA; McNeese M; Schultz DJ; Fowble BL; Barrett W; Yeh IT; Kurtz JM; Amalric R; Fourquet A
    Cancer J Sci Am; 1996; 2(3):158-65. PubMed ID: 9166516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases.
    Komoike Y; Akiyama F; Iino Y; Ikeda T; Akashi-Tanaka S; Ohsumi S; Kusama M; Sano M; Shin E; Suemasu K; Sonoo H; Taguchi T; Nishi T; Nishimura R; Haga S; Mise K; Kinoshita T; Murakami S; Yoshimoto M; Tsukuma H; Inaji H
    Cancer; 2006 Jan; 106(1):35-41. PubMed ID: 16333848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.
    van Nes JG; Putter H; Julien JP; Tubiana-Hulin M; van de Vijver M; Bogaerts J; de Vos M; van de Velde CJ;
    Breast Cancer Res Treat; 2009 May; 115(1):101-13. PubMed ID: 18484198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Breast-conserving treatment for early invasive lobular breast cancer: 15 years results].
    Fodor J; Sulyok Z; Polgár C; Major T; Tóth J; Németh G
    Magy Seb; 2001 Aug; 54(4):209-14. PubMed ID: 11550486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loco regional failure pattern after lumpectomy and breast irradiation in 4,185 patients with T1 and T2 breast cancer. Implications for nodal irradiation.
    Livi L; Paiar F; Simontacchi G; Barca R; Detti B; Fondelli S; Bastiani P; Santini R; Scotti V; Bianchi S; Cataliotti L; Mungai V; Biti G
    Acta Oncol; 2006; 45(5):564-70. PubMed ID: 16864170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.